Abstract: An 2-benzo-[3,4-b]quinolino-[b,g]indeno[1?,2?:3,4]fluoreno-[1,2-d]oxonine-24-flouro-5,11,16,21-tetraone compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.

Abstract: An ethyl 2-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetate compound, its synthesis, and its use as an antimicrobial agent.

Abstract: An ethyl 3-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)propanoate compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.

Abstract: The invention provides a compound of formula I, formula II, or formula III: or a salt thereof, wherein R1-R10 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as HIV-1 CA-targeting molecules and as antiviral agents.

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

Abstract: The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.

Abstract: Compositions for killing insects (the term “insects” as used herein includes non-insects such as ticks, mites, spiders, centipedes, scorpions, chiggers, and solifugids), said composition containing at least one compound of formula 1 wherein R1 is CH3, C2H5, C3H7; saturated or unsaturated, straight or branched, or halogen substituted alkyl; and wherein R2 are independently H, halogen, nitrogen, oxygen, sulfur, saturated or unsaturated, straight or branched alkyl, alkenyl, alkyl halide, aldehyde, ketone, ether, ester, amine, or amide; optionally methyl benzoate, optionally a surfactant, and optionally a carrier. Also disclosed are methods for killing insects, involving treating an object or area with an insect killing effective amount of the compositions, optionally methyl benzoate, optionally a surfactant, and optionally a carrier.

Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Abstract: A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Abstract: The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described. The methods involve the administration of drug(s) that induce oxidative stress in cancer cells, in conjunction with melphalan on a defined schedule.

Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.

Abstract: Disclosed herein are therapeutic methods of administering compounds that modulate the C—C chemokine receptor type 4 (CCR4) for the treatment of Epstein Bar virus (EBV) positive cancers and malignancies.

Abstract: Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a disease caused by oral bacteria in an animal wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or a pharmaceutically acceptable salt thereof. A cosmetic method of preventing or decreasing oral staining in an animal, comprising the step of exposing the oral cavity to a morpholino compound of general.

Abstract: Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.

Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

Abstract: The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.